FDA Approves First Generic of Tazorac Gel
Commercial shipments are already under way of Cosette’s gel formulation of tazarotene to treat patients with acne and facial wrinkles.
The FDA has approved Cosette Pharmaceuticals’ abbreviated new drug application (ANDA) for the first generic versions of Almirall’s Tazorac (tazarotene) gel, 0.05% and 0.1%, which is used to treat psoriasis, acne, and sun damage to skin. The company has received 180 days competitive generic therapy (CGT) exclusivity.
Apurva Saraf
“This approval and immediate launch represents an important milestone in the evolution of Cosette. Since we reset and refocused our R&D efforts in mid-2020, we now have several niche ANDAs pending with the FDA and look forward to the future approvals and launches,” Apurva Saraf, president and chief executive officer of Cosette Pharma, said in a press release.
Tazarotene is a retinoid product related to vitamin A. Generics of the cream formulation are available from Cosette and Taro. The lowest retail price of the cream formulation is about $40 through mail order, according to GoodRx.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
